ArticleCureus2024
C-Reactive Protein/Albumin Ratio and Clinicopathological Features in Ovarian Cancer: A Prospective Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison of Frozen Section and Final Pathology Results in Borderline Ovarian Tumors: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Development and evaluation of a nomogram prediction model for invasion and metastasis in primary liver cancer based on serum CD147 and IL-6.Frontiers in oncology · 2025Article
- Prognostic Impact of Pre-Treatment CRP/Albumin Ratio in Patients with Advanced-Stage Epithelial Ovarian Cancer.OncoTargets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Evidence suggests inflammation plays a key role in the development of ovarian malignancy. This study investigated the relationship between the C-reactive protein (CRP) to serum albumin (Alb) ratio and clinicopathological parameters in ovarian cancer patients. The goal was to determine if this readily measurable inflammatory marker could provide insights into disease severity. Methods A prospective study of 94 patients with histopathologically confirmed ovarian cancer (diagnosed between November 2020 and December 2023) investigated the relationship between the pretreatment C-reactive protein to albumin ratio (CRP/Alb), and various clinicopathological characteristics, including age, distant metastasis, lymph node involvement, ascites, tumor grade, and surgical stage. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic accuracy of the CRP/Alb ratio and establish a cutoff value. Results Patients with metastasis, lymph node involvement, ascites, higher tumor grade, and advanced stages (III and IV) had significantly higher median CRP/Alb ratios compared to those without these features (1.43 vs. 0.78, 1.47 vs. 0.51, 1.16 vs. 0.46, 1.46 vs. 0.52, and stages I/II (0.49/0.95) vs. stages III/IV (1.47/1.58), respectively; all p < 0.001). ROC analysis determined an optimal cutoff value of 1.08. A preoperative CRP/Alb ratio above this cutoff indicated severe disease based on clinicopathological parameters. Conclusion In conclusion, elevated pretreatment CRP/Alb ratios correlated with more severe and advanced ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.